Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1969 1
1971 1
1979 3
1980 1
1981 1
1982 1
1983 2
1984 3
1985 4
1986 3
1987 4
1988 3
1989 1
1990 6
1991 6
1992 3
1993 8
1994 3
1995 6
1996 2
1997 6
1998 5
1999 13
2000 11
2001 13
2002 9
2003 11
2004 36
2005 13
2006 22
2007 21
2008 25
2009 23
2010 31
2011 30
2012 37
2013 31
2014 36
2015 46
2016 42
2017 46
2018 46
2019 70
2020 92
2021 92
2022 84
2023 105
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

961 results

Results by year

Filters applied: . Clear all
Page 1
Neuroendocrine tumor theranostics.
Ichikawa Y, Kobayashi N, Takano S, Kato I, Endo K, Inoue T. Ichikawa Y, et al. Cancer Sci. 2022 Jun;113(6):1930-1938. doi: 10.1111/cas.15327. Epub 2022 Apr 11. Cancer Sci. 2022. PMID: 35271754 Free PMC article. Review.
Somatostatin analogs bind to somatostatin receptor, and when combined with diagnostic radionuclides, such as gamma-emitters, are utilized for diagnosis of neuroendocrine tumor. Somatostatin receptor scintigraphy when combined with therapeutic radionuclides, such as beta- …
Somatostatin analogs bind to somatostatin receptor, and when combined with diagnostic radionuclides, such as gamma-emitters, are util …
Non-FDG PET/CT.
Lopci E, Fanti S. Lopci E, et al. Recent Results Cancer Res. 2020;216:669-718. doi: 10.1007/978-3-030-42618-7_20. Recent Results Cancer Res. 2020. PMID: 32594402 Review.
The major applications for molecular imaging with PET in clinical practice concern cancer imaging. Undoubtedly, 18F-FDG represents the backbone of nuclear oncology as it remains so far the most widely employed positron emitter compound. The acquired knowledge on can …
The major applications for molecular imaging with PET in clinical practice concern cancer imaging. Undoubtedly, 18F-FDG represents th …
"Evidence-based Tweeting" in Vascular Surgery.
Argyriou C, Lazarides MK, Georgiadis GS. Argyriou C, et al. Ann Vasc Surg. 2020 Oct;68:542-544. doi: 10.1016/j.avsg.2020.06.024. Epub 2020 Jun 17. Ann Vasc Surg. 2020. PMID: 32562831 Review.
We performed a search on Twitter collecting tweets containing the keywords "peripheral arterial disease" and "abdominal aortic aneurysm" separately and including 3 types of emitters. Our aim was to assess the dissemination of these 2 major vascular entities across t …
We performed a search on Twitter collecting tweets containing the keywords "peripheral arterial disease" and "abdominal aortic aneurysm" sep …
Alpha-particle microdosimetry.
Chouin N, Bardies M. Chouin N, et al. Curr Radiopharm. 2011 Jul;4(3):266-80. doi: 10.2174/1874471011104030266. Curr Radiopharm. 2011. PMID: 22201713 Review.
With the increasing availability of alpha emitters, targeted alpha-particle therapy has emerged as a solution of choice to treat haematological cancers and micrometastatic and minimal residual diseases. ...This last factor represents a major limitation to the use of …
With the increasing availability of alpha emitters, targeted alpha-particle therapy has emerged as a solution of choice to treat haem …
Radiopharmaceuticals for Treatment of Osteosarcoma.
Anderson PM. Anderson PM. Adv Exp Med Biol. 2020;1257:45-53. doi: 10.1007/978-3-030-43032-0_4. Adv Exp Med Biol. 2020. PMID: 32483729 Review.
Although osteosarcoma, a bone-forming cancer, would seem ideally suited to be treated with bone seekers, patterns of relapse involving non-ossifying metastases remain a major problem to be overcome. Thus, this review will not only describe experience using a number of bone …
Although osteosarcoma, a bone-forming cancer, would seem ideally suited to be treated with bone seekers, patterns of relapse involving non-o …
Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM. Guerra Liberal FDC, et al. Cancer Biother Radiopharm. 2020 Aug;35(6):404-417. doi: 10.1089/cbr.2020.3576. Epub 2020 Jun 16. Cancer Biother Radiopharm. 2020. PMID: 32552031 Review.
However, targeted alpha therapy (TAT) is gaining more attention as new targets, synthetic chemistry approaches, and alpha particle emitters are identified, constructed, developed, and realized. From a radiobiological perspective, alpha particles are more effective at killi …
However, targeted alpha therapy (TAT) is gaining more attention as new targets, synthetic chemistry approaches, and alpha particle emitte …
Targets for Therapy of Bladder Cancer.
Seidl C. Seidl C. Semin Nucl Med. 2020 Mar;50(2):162-170. doi: 10.1053/j.semnuclmed.2020.02.006. Epub 2020 Feb 29. Semin Nucl Med. 2020. PMID: 32172801 Review.
Another approach that has been successfully established in preclinical studies uses the cytotoxic power of the alpha-emitter Bi-213 coupled to an antibody targeting EGFR. Overexpression of EGFR has been demonstrated in the majority of patients suffering from CIS. .. …
Another approach that has been successfully established in preclinical studies uses the cytotoxic power of the alpha-emitter Bi-213 c …
Cancer risk following alpha-emitter exposure.
Tirmarche M. Tirmarche M. Ann ICRP. 2018 Oct;47(3-4):115-125. doi: 10.1177/0146645318756247. Epub 2018 Apr 16. Ann ICRP. 2018. PMID: 29658289
Three major alpha emitters were considered: radon and its decay products, plutonium, and uranium. Results came mainly from cohorts of workers, while for radon, major studies of the general population contributed to a better understanding of the risk of lung c …
Three major alpha emitters were considered: radon and its decay products, plutonium, and uranium. Results came mainly from coh …
Anti-HER2 radioimmunotherapy.
Brechbiel MW, Waldmann TA. Brechbiel MW, et al. Breast Dis. 2000;11:125-32. doi: 10.3233/bd-1999-11111. Breast Dis. 2000. PMID: 15687598
Due to the limitations of radio-iodine ((131)I), metallic radionuclides (e.g, the beta(-)-emmiter (90)Y or the alpha-emitters (213)Bi, (212)Bi, (212)Pb) linked to mAb's are being evaluated in murine models. Complete elimination of beast cancer xenografts was possible in an …
Due to the limitations of radio-iodine ((131)I), metallic radionuclides (e.g, the beta(-)-emmiter (90)Y or the alpha-emitters (213)Bi …
Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
Sgouros G, Hobbs R, Josefsson A. Sgouros G, et al. Curr Radiopharm. 2018;11(3):209-214. doi: 10.2174/1874471011666180426130058. Curr Radiopharm. 2018. PMID: 29697036 Review.
The high energy deposition density along an alpha-particle track causes a spectrum of DNA lesions. The majority of these are irreparable DNA double-stranded breaks. Accordingly the biologic effects of alpha- particles are largely impervious to the adaptive and resistance m …
The high energy deposition density along an alpha-particle track causes a spectrum of DNA lesions. The majority of these are irrepara …
961 results